ReviewTranslational stroke research2026
Targeting DNA Damage and Repair Pathways in Cerebral Ischemic Stroke: From Bench to Bedside.
Review in Translational stroke research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Zinc dyshomeostasis, mitochondrial dysfunction, and their pathological cycle in ischemic stroke pathophysiology: Mechanisms and potential therapeutic targets.Redox biology · 2026Review
- Astrocytic Redox Homeostasis as a Metabolic Modulator of DNA Damage and Repair in the Ischemic Penumbra.Cells · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Despite advances in reperfusion therapies following cerebral ischemic stroke, effective treatment options remain limited, and achieving optimal outcomes post-revascularization continues to be a significant challenge. Increasing evidences have highlighted the crucial role of DNA damage and its associated downstream inflammatory and apoptotic pathways in the pathophysiology of stroke (collectively known as the DNA damage response, DDR). Enhancing DNA repair has emerged as a promising therapeutic approach to mitigate neural injury and promote function recovery after stroke. This review summarizes recent strategies aimed at neuroprotection through the modulation of DNA damage and repair pathways, focusing on both clinical patients with ischemic stroke and experimental stroke models. Additionally, we explore potential future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.